TRDA Entrada Therapeutics, Inc.
Price Chart
Executive Summary
Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVATE-45-201 Phase 1/2 study for ENTR-601-45 in Duchenne muscular dystrophy (exon 45). The company remains on track to report Cohort 1 safety, PK, and dystrophin data in mid-2026, with Cohort 2 and 3 data to follow. This is a routine clinical progress update with no new efficacy data released, making the near-term impact neutral.
Actionable Insight
Monitor mid-2026 for Cohort 1 dystrophin data, which will be the first efficacy readout for ENTR-601-45. Positive dystrophin expression could drive significant upside for this single-asset-stage biotech; negative or ambiguous data would be highly bearish. Until then, no near-term catalyst.
Key Facts
- DMC recommended initiation of Cohort 2 at 10 mg/kg (up from 5 mg/kg in Cohort 1) after reviewing safety and PK data from 8 participants.
- Company on track to report Cohort 1 data (safety, early PK, dystrophin) in mid-2026.
- ELEVATE-45-201 is a Phase 1/2 MAD study of ENTR-601-45 for DMD patients amenable to exon 45 skipping.
- Dosing regimen is once every six weeks; planned doses across three cohorts range from 5 mg/kg to 15 mg/kg.
- No financial data, revenue, or earnings were disclosed in the press release.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Cohort 1 data (mid-2026) may show insufficient dystrophin expression or safety signals, leading to program termination.
- DMD exon 45 space is competitive (Sarepta's Casimersen already approved); differentiation on efficacy or dosing frequency is unproven.
- Pre-revenue company with limited cash runway — future dilution risk for ongoing trials.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304981 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
8-K
| $5.96 awaiting T+1 | awaiting T+1 | — | $6.46 (+8.39%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $6.64 $6.58 | ▼ −0.90% | ▼ −0.18% | $6.46 (−2.71%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.85 $6.84 | ▼ −0.15% | ▼ −0.98% | $6.46 (−5.69%) |
|
May 4, 2026
5w ago
|
144
| $15.75 $16.03 | ▲ +1.78% | ▲ +0.39% | $6.46 (−58.98%) |
|
May 4, 2026
6w ago
|
Insider Cluster
| $15.79 $15.75 | ▲ +0.25% | ▲ +1.05% | $6.46 (+59.09%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $12.63 $12.96 | ▲ +2.61% | ▲ +2.45% | $6.46 (−48.85%) |
|
Mar 4, 2026
14w ago
|
Insider Cluster
| $12.50 $11.62 | ▼ −7.04% | ▼ −6.47% | $6.46 (−48.32%) |
|
Feb 26, 2026
15w ago
|
8-K
| $12.79 $11.93 | ▲ +6.72% | ▲ +6.27% | $6.46 (+49.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access